DEAL ANNOUNCEMENT
McDermott advises NORD Holding on the acquisition of alfavet Group
Nov 19, 2026
Read time: 3 min
With a team led by Holger Ebersberger, McDermott Will & Schulte has represented funds advised by NORD Holding on the acquisition and acquisition financing of alfavet Group (“alfavet”).
Headquartered in Neumünster, Germany, alfavet is the leading provider of veterinary pharmaceuticals and nutraceuticals in the German veterinary channel. Founded in 2003, the group has established itself as a key partner to veterinary practices. Its portfolio includes veterinary pharmaceuticals, nutraceuticals, and care products covering areas such as gastrointestinal, renal and urinary tract, and cardiovascular health. With its own production facility in Neumünster, alfavet also serves third-party customers as a contract development and manufacturing organization (CDMO).
Together with CEO and shareholder Konstantin Wree, NORD Holding aims to develop alfavet into the leading European animal health platform. The partnership is intended to support continued organic growth, expansion into selected European markets, and targeted acquisitions to broaden the product portfolio and enter new markets. The existing shareholders will remain invested in the business.
The McDermott team was led by Holger H. Ebersberger (Private Equity) and Matthias Weissinger (Finance), and included partners Hanno M. Witt, LL.M., Florian Schiefer, Jana Grieb, counsel Manuel Weiß, as well as associates: Macha Dinga, Armin Teymouri, Tobias Thiemann, Svenja Hefner, Alina Dietrich, Bastiaan Wolters, Alina Affeld, Yves Kandel, Thomas Hintzen, Merlyn von Hugo, and Luca Goldschmidt.